media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

A New Era Dawns

The anticoagulation field has given rise to global blockbuster drugs. For instance, apixaban generated global sales of over $20 billion in 2025. Following the iterations of warfarin and non vitamin K antagonist oral anticoagulants (NOACs), the direction for next generation anticoagulants is now clear: FXI/FXIa inhibitors are set to become an entirely new option in anticoagulation therapy. Recently, Bayer also announced that its FXIa inhibitor asundexian achieved breakthrough positive results in pivotal Phase III clinical trials.The era of FXI/FXIa inhibitors has officially begun. 01Breaking the Deadlock Thrombotic diseases are a group of disorders characterized by the formation of pathological blood clots in arteries or veins. They have become one of the leading global causes of death, directly linked to roughly one quarter of all deaths worldwide each year. According to Frost & Sullivan data, the global number of incident cases of thrombotic diseases reached 26.7 million in 2024, with 7 ...
- Source: drugdu
- 26
- February 26, 2026
Junshi Biosciences and Antengene Corporation Forge Clinical Research Cooperation in Oncology

On February 25, Junshi Biosciences announced a strategic collaboration with Antengene Corporation to jointly explore the synergistic potential of the combination therapy involving Junshi Biosciences’ independently developed JS207 (anti-PD-1/VEGF bispecific antibody) and Antengene’s ATG-037 (oral small-molecule CD73 inhibitor) in cancer patients in Chinese Mainland.JS207 is a recombinant humanized anti-PD-1 and VEGF bispecific antibody independently developed by Junshi Biosciences. It has demonstrated encouraging anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. Preclinical studies have validated its prominent anti-tumor efficacy in multiple tumor models and supported its differentiated mechanism of action. Studies have shown that VEGFA can enhance the antigen-binding activity, T-cell activation potency, and endocytosis of cell-surface PD-1 by JS207. In a poster presentation at the European Society for Medical Oncology Asia (ESMO Asia) 2025, JS207 monotherapy exhibited promising efficacy across multiple solid tumors. Among 62 PD-L1-positive non-small cell lung cancer (NSCLC) patients receiving first-line treatment, ...
- Source: drugdu
- 26
- February 26, 2026
Qilu Pharmaceutical achieves another breakthrough in internationalization, with its blockbuster anti-tumor drug bevacizumab approved for marketing in the UK.

At the beginning of the new year, Qilu Pharmaceutical achieved a new breakthrough in its internationalization strategy. Bevacizumab injection (trade name: Ankevda) received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of various malignant tumors, such as metastatic colorectal cancer, non-small cell lung cancer, breast cancer, kidney cancer, ovarian cancer, and cervical cancer. The UK is a major global pharmaceutical market, and this approval marks the entry of this blockbuster anti-tumor drug into the high-end market. High-quality biopharmaceuticals “Made in China” are gaining widespread recognition worldwide and benefiting more patients. As the world’s first anti-angiogenic monoclonal antibody, bevacizumab is a first-line standard treatment recommended by multiple NCCN guidelines for non-small cell lung cancer and colorectal cancer. Bevacizumab exerts its anti-tumor effects primarily through three mechanisms: inhibiting the degradation of existing vascular systems, suppressing angiogenesis, and reducing vascular permeability. Due to its unique mechanism ...
- Source: drugdu
- 32
- February 26, 2026
Etoposide Injection and Fluorouracil Injection Receive FDA Approval in the United States

Huiyu Pharmaceutical announced on February 25th that it recently received notification from the U.S. Food and Drug Administration (FDA) that its New Drug Applications (NDAs) for etoposide injection and fluorouracil injection have been approved. This means the company can now manufacture and sell these products in the U.S. market through its overseas partners. Etoposide injection is a topoisomerase inhibitor, used in conjunction with other chemotherapy and/or immunotherapy treatments. When used in combination, this treatment is indicated for the following adult patients: 1. Refractory testicular cancer; 2. Small cell lung cancer. Fluorouracil injection is indicated for the treatment of: 1. Colon and rectal cancer; 2. Breast cancer; 3. Gastric adenocarcinoma; 4. Pancreatic cancer. https://finance.eastmoney.com/a/202602253654068331.html
- Source: drugdu
- 29
- February 26, 2026
Jikeqin’s marketing application accepted by the drug regulatory authority

On February 25, Jiuyuan Gene (02566) issued an announcement stating that the marketing application of its developed product, Jikeqin®, has been accepted by the National Medical Products Administration of the People’s Republic of China. This product is a biosimilar of the long-acting glucagon-like peptide receptor agonist smegglutide, designed for weight management in obese or overweight individuals. Glucose control and weight management are achieved by mimicking the physiological effects of endogenous GLP-1 hormones, which promote insulin secretion, inhibit glucagon release, suppress appetite, and delay gastric emptying. In the ongoing Phase III clinical trials, the clinical equivalence study of clopidogrel in obese subjects showed that its primary efficacy endpoint (the rate of change in weight from baseline after 44 weeks of treatment) and safety were clinically equivalent to the reference drug, demonstrating good efficacy and tolerability. https://finance.eastmoney.com/a/202602263654818764.html
- Source: drugdu
- 29
- February 26, 2026
Net profit surged by 1041%, marking a breakthrough for the self-exempt king

Today (February 25), 3SBio released its 2025 preliminary financial results: it expects to achieve revenue of RMB 4.199 billion, a year-on-year increase of 251.81%; net profit attributable to the parent company of RMB 2.939 billion, a year-on-year increase of 317.09%; and net profit attributable to the parent company excluding non-recurring items of RMB 2.805 billion, a year-on-year increase of 1041.01% . However, the story behind the numbers is far more fascinating than the numbers themselves . From the growing pains of strategic transformation in 2022 to the explosive turnaround in performance in 2025, 3SBio has forged a highly representative growth path for innovative Chinese enterprises. 01 Behind the surge in net profit In its preliminary earnings report, 3SBio disclosed that the significant increase in its revenue and net profit in 2025 was due to the important cooperation reached between the company and Pfizer during the reporting period . The company ...
- Source: drugdu
- 29
- February 26, 2026
Kanghong Pharmaceutical’s Class 1 new drug receives clinical trial approval

On February 25, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced on its website that KHN707 tablets, a Class 1 new chemical drug submitted by Chengdu Kanghong Pharmaceutical Group Co., Ltd., has been approved for clinical trials . This is an oral small-molecule selective orexin receptor (OX2R) antagonist independently developed by Kanghong Pharmaceutical . The approved indication for clinical trials is insomnia , and it has shown sleep-promoting effects in various insomnia efficacy models in preclinical studies. Insomnia patients mainly experience difficulty falling asleep, sleep maintenance disorders, and reduced total sleep time. Persistent insomnia can cause symptoms such as low mood, poor memory, and difficulty concentrating, not only affecting daily life and work but also leading to other central nervous system disorders, such as varying degrees of depression. According to data from the “Guidelines for the Diagnosis and Treatment of Insomnia in Chinese Adults ...
- Source: drugdu
- 28
- February 26, 2026
HOSPITALAR

Organiser：Informa Group Time：May 19 – 22, 2026 Address：Centro de Exposições Imigrantes, Rodovia dos Imigrantes, Km 1.5, São Paulo – SP Exhibition hall：São Paulo Expo Product range: Medical Equipment Zone: Hospital technical facilities and equipment; medical clinic technology and equipment; ward furniture and equipment; diagnostic and therapeutic equipment; biochemical and laboratory testing equipment; pharmaceutical products; hygiene materials; medical communication technology and equipment; comprehensive hospital information technology and services. Disabled Rehabilitation Technology Zone: Nursing equipment; nursing products; communication technology; mobile care; nursing services; medical technology; orthopedic surgical technology; outpatient care; physiotherapy; prosthetics; services; ergonomic therapy; communication technology; wheelchairs. Pharmaceutical Zone: Prescription drugs; traditional Chinese patent medicines; Western medicines; antibiotics; powder injections; infusions; tablets; ointments; capsules; various new drugs; special drugs; national protected traditional Chinese medicines; national essential medical insurance drugs; pharmaceutical raw materials; various intermediates; biochemical reagents and vaccines; various biological products. Dental Zone: Dental instruments & equipment; dental pharmaceuticals & raw ...
- Source: drugdu
- 32
- February 26, 2026
Bio-Thera Solutions’ innovative drug, Darpubayimab injection, has had its marketing authorization application accepted by the NMPA

Bio-Thera Solutions, Ltd. (SSE: 688177 ) is a global, science-driven biopharmaceutical company located in Guangzhou, China, hereinafter referred to as ” Bio-Thera ” or ” the Company ” . The Company’s marketing authorization application for its product, darpubayimab injection (hereinafter referred to as “BAT4406F” ), for the treatment of neuromyelitis optica spectrum disorder (NMOS D ) positive for anti-aquaporin 4 (AQP4) antibodies, has recently been accepted by the National Medical Products Administration. In July 2025, the interim analysis of the pivotal Phase II/III registration clinical trial of BAT4406F in neuromyelitis optica spectrum disorders (NMOSD) showed significant benefit in the experimental group, leading to a recommendation from the Independent Data Monitoring Committee (IDMC) to “terminate the trial early,” thus ending participant recruitment early. The BLA application was completed in early February 2026. NMOSD is a rare autoimmune disease characterized by high relapse and high disability rates. Its core clinical manifestations include ...
- Source: drugdu
- 36
- February 25, 2026
Dashi Pharmaceuticals licenses its migraine medication to NewCo in the United States.

On February 25th, Dashi Pharmaceutical announced an exclusive licensing agreement with Slate Medicines, a rising US biopharmaceutical company operating under the NewCo model. Dashi Pharmaceutical will exclusively license the global clinical development and commercialization rights outside of Greater China to Slate Medicines for its independently developed monoclonal antibody DS009 (SLTE-1009), which targets pituitary adenylate cyclase-activating peptide (PACAP). This drug will be used for the prevention and treatment of headaches such as migraines, and will also become the first domestically developed non-opioid biological analgesic to be exported. Slate Medicines has simultaneously completed a $130 million Series A funding round, co-led by leading US healthcare investment firms including RA Capital Management, Forbion, and Foresite Capital. The funds will primarily be used to advance the global clinical development of DS009. The company is led by CEO Gregory Oakes, who has over 30 years of industry experience. Mr. Oakes also recently served as a ...
- Source: drugdu
- 38
- February 25, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.